BioMarin Pharmaceutical Inc. reaffirmed earnings guidance for the year 2022. For the year, the company expects total revenues to be in the range of $2,060 million to $2,160 million and GAAP net income to be in the range of $105 million to $145 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88.63 USD | -1.60% | -3.89% | -8.08% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.08% | 17.09B | |
-5.99% | 84.46B | |
+2.76% | 40.85B | |
-24.88% | 27.69B | |
+53.61% | 24.28B | |
-33.74% | 13.67B | |
-16.63% | 11.86B | |
-11.19% | 11.79B | |
-2.25% | 8.07B | |
+1.05% | 7.51B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022